ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Reports Mixed Q2 2025 Results with Revenue Beat but EPS Miss, Shares Drop 9% in Pre-Market Anika Therapeutics reported mixed Q2 2025 results, with revenue beating estimates but EPS missing. Shares fell 9% amid Hyalofast trial concerns despite strong regenerative solutions growth.
US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert U.S. stock futures fell again on Thursday after a brief respite on Wednesday, following a softer-than-expected inflation print.
ANIK Stock Earnings: Anika Therapeutics Beats EPS, Misses Revenue for Q2 2024 ANIK stock results show that Anika Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
ANIK Stock Earnings: Anika Therapeutics Beats EPS, Beats Revenue for Q1 2024 ANIK stock results show that Anika Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Earnings Scheduled For March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (
NASDAQ:SGMO ) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
3 Sorry Penny Stocks to Sell in August Before It’s Too Late As interest rates rise and money becomes more expensive, investors may look to get rid of these penny stocks set to fail.
7 Stocks to Buy Before the Market Starts to Soar in 2023 With the market falling into a bit of disarray, astute investors can leverage this moment to dive into compelling stocks to buy.
